{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:16:36Z","timestamp":1792782996148,"version":"4.5.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundaci\u00f3 Instituci\u00f3 dels Centres de Recerca de Catalunya","id":[{"id":"https:\/\/ror.org\/01bkbaq61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Marfan syndrome (MFS), a multisystemic connective tissue disorder, shows intra- and interfamilial aortopathy variability. More than 3,000 mutations have been reported in the\n                    <jats:italic>FBN1<\/jats:italic>\n                    gene, which encodes fibrillin-1, a component of microfibrils and elastic fibres. Aortic dilatation mainly affects the aortic root and the ascending aorta. However, dissection of the aortic wall can occur either before or after the aortic arch (type A and type B dissections, respectively). There is no doubt that progress in aortic surgery has significantly improved patients\u2019 life expectancy, but conversely, current medical treatment based on beta-blockers (BBs) and angiotensin receptor blockers (ARBs) only slightly slows aortic growth. Aortopathy is the result of multiple defects in cellular and subcellular processes that affect aortic wall cells and extracellular matrix homeostasis and organisation. Pathomechanisms include dysregulated cell signalling, altered mechanotransduction, and oxidative stress. Therefore, it is reasonable to consider a multi-target strategy for medical treatment. Here, we suggest the concurrent administration of allopurinol with current medical treatment. Allopurinol\u2019s mode of action is based on its strong antioxidant effects, demonstrated in preclinical assays in different MFS mouse models. Allopurinol is a widely used compound in medical practice for gout, and has been proven safe, economical and effective in other cardiovascular diseases. The recent approval of allopurinol as an orphan drug for the treatment of MFS by the European Medicines Agency (EMA) adds further value to its potential inclusion in standard medical therapy in the near future.\n                  <\/jats:p>","DOI":"10.1007\/s10557-026-07954-8","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:45:27Z","timestamp":1789623927000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5242-150X","authenticated-orcid":false,"given":"Gustavo","family":"Egea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Barbosa","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Teixid\u00f3-Tur\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Mas-Stachurska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Loeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"7954_CR1","doi-asserted-by":"publisher","first-page":"1302285","DOI":"10.3389\/fcell.2023.1302285","volume":"11","author":"L Li","year":"2024","unstructured":"Li L, Huang J, Liu Y. The extracellular matrix glycoprotein fibrillin-1 in health and disease. Front Cell Develop Biol. 2024;11:1302285. https:\/\/doi.org\/10.3389\/fcell.2023.1302285.","journal-title":"Front Cell Develop Biol"},{"issue":"1","key":"7954_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41572-021-00298-7","volume":"7","author":"DM Milewicz","year":"2021","unstructured":"Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7(1):64. https:\/\/doi.org\/10.1038\/s41572-021-00298-7.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"7954_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.102051","volume":"4","author":"Z Xu","year":"2025","unstructured":"Xu Z, Li Z, Xiang L, et al. Phenotypic diversity of Marfan syndrome. J Am Coll Cardiol. 2025;4(9):102051. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102051.","journal-title":"J Am Coll Cardiol"},{"issue":"2025","key":"7954_CR4","doi-asserted-by":"publisher","first-page":"326230","DOI":"10.1136\/heartjnl-2025-326230","volume":"2026","author":"JFA de Backer","year":"2026","unstructured":"de Backer JFA, Muino-Mosquera L, Rodriguez-Palomares JF, Teixido-Tura G. Diagnosis and management of heritable thoracic aortic diseases. Heart. 2026;2026(2025):326230. https:\/\/doi.org\/10.1136\/heartjnl-2025-326230.","journal-title":"Heart"},{"key":"7954_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13073-024-01423-3","volume":"16","author":"A Drackley","year":"2024","unstructured":"Drackley A, Somerville C, Arnaud P, et al. Interpretation and classification of FBN1 variants associated with Marfan syndrome: consensus recommendations from the Clinical Genome Resource\u2019s FBN1 variant curation expert panel. Genome Med. 2024;16:154. https:\/\/doi.org\/10.1186\/s13073-024-01423-3.","journal-title":"Genome Med"},{"issue":"3","key":"7954_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJM199007193230304","volume":"323","author":"DW Hollister","year":"1990","unstructured":"Hollister DW, Godfrey M, Sakai LY, et al. Immunohistologic Abnormalities of the Microfibrillar-Fiber System in the Marfan Syndrome. New Engl J Med. 1990;323(3):152\u20139. https:\/\/doi.org\/10.1056\/NEJM199007193230304.","journal-title":"New Engl J Med"},{"key":"7954_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/352337a0","volume":"352","author":"HC Dietz","year":"1991","unstructured":"Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337\u20139. https:\/\/doi.org\/10.1038\/352337a0.","journal-title":"Nature"},{"issue":"1","key":"7954_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-020-01604-4","volume":"16","author":"A Paglialonga","year":"2021","unstructured":"Paglialonga A, Gaetano R, Robert L, et al. eHealth for patients with rare diseases: the eHealth Working Group of the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN). Orph J Rare Dis. 2021;16(1):164. https:\/\/doi.org\/10.1186\/s13023-020-01604-4.","journal-title":"Orph J Rare Dis"},{"issue":"24","key":"7954_CR9","doi-asserted-by":"publisher","first-page":"E334","DOI":"10.1161\/CIR.0000000000001106","volume":"146","author":"EM Isselbacher","year":"2022","unstructured":"Isselbacher EM, Preventza O, Black JH, et al. 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146(24):E334\u201382. https:\/\/doi.org\/10.1161\/CIR.0000000000001106.","journal-title":"Circulation"},{"issue":"5","key":"7954_CR10","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/j.jtcvs.2023.04.023","volume":"166","author":"EM Isselbacher","year":"2023","unstructured":"Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC\/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023;166(5):e182\u2013331. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.04.023.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"7954_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/HCO.0000000000001126","volume":"39","author":"E Monda","year":"2024","unstructured":"Monda E, Caiazza M, Limongelli G. The role of genetic testing in Marfan syndrome. Curr Opin Cardiol. 2024;39(3):162\u20139. https:\/\/doi.org\/10.1097\/HCO.0000000000001126.","journal-title":"Curr Opin Cardiol"},{"issue":"36","key":"7954_CR12","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700. https:\/\/doi.org\/10.1093\/eurheartj\/ehae179.","journal-title":"Eur Heart J"},{"key":"7954_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae526","author":"L Mui\u00f1o-Mosquera","year":"2024","unstructured":"Mui\u00f1o-Mosquera L, Cervi E, De Groote K, et al. Management of aortic disease in children with FBN1 -related Marfan syndrome. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae526.","journal-title":"Eur Heart J"},{"issue":"7","key":"7954_CR14","doi-asserted-by":"publisher","first-page":"101921","DOI":"10.1016\/j.jacadv.2025.101921","volume":"4","author":"N Narula","year":"2025","unstructured":"Narula N, Weinsaft JW, Devereux RB, et al. The Evidence Surrounding Type B Dissection in Marfan Syndrome: Miles to Go Before We Sleep. JACC Adv. 2025;4(7):101921. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101921.","journal-title":"JACC Adv"},{"issue":"9","key":"7954_CR15","doi-asserted-by":"publisher","first-page":"e048274","DOI":"10.1161\/JAHA.125.048274","volume":"15","author":"N Narula","year":"2026","unstructured":"Narula N, Devereux RB, Ma X. Outcomes of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry. J Am Heart Assoc. 2026;15(9):e048274. https:\/\/doi.org\/10.1161\/JAHA.125.048274.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"7954_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/ejcts\/ezv073","volume":"49","author":"R Hetzer","year":"2016","unstructured":"Hetzer R, Siegel G, Delmo Walter EM. Cardiomyopathy in Marfan syndrome. Eur J Cardiothorac Surg. 2016;49(2):561\u20138. https:\/\/doi.org\/10.1093\/ejcts\/ezv073.","journal-title":"Eur J Cardiothorac Surg"},{"key":"7954_CR17","doi-asserted-by":"publisher","first-page":"682390","DOI":"10.3389\/fped.2021.682390","volume":"9","author":"L Mui\u00f1o-Mosquera","year":"2021","unstructured":"Mui\u00f1o-Mosquera L, De Backer J. Cardiomyopathy in Genetic Aortic Diseases. Front Pediatr. 2021;9:682390. https:\/\/doi.org\/10.3389\/fped.2021.682390.","journal-title":"Front Pediatr"},{"issue":"9","key":"7954_CR18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29800","volume":"14","author":"J Singh","year":"2022","unstructured":"Singh J, Wanjari A. Cardiac complications in Marfan syndrome: a review. Cureus. 2022;14(9):e29800. https:\/\/doi.org\/10.7759\/cureus.29800.","journal-title":"Cureus"},{"issue":"4","key":"7954_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1038\/s41390-025-03899-0","volume":"98","author":"AM Wolf","year":"2025","unstructured":"Wolf AM, Wilhelm CM, Strainic J, Mead TJ. Is cardiomyopathy intrinsic to Marfan syndrome? Pediatr Res. 2025;98(4):1201. https:\/\/doi.org\/10.1038\/s41390-025-03899-0. 2.","journal-title":"Pediatr Res"},{"issue":"9","key":"7954_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.5435\/00124635-200909000-00004","volume":"17","author":"ED Shirley","year":"2009","unstructured":"Shirley ED, Sponseller PD. Marfan syndrome. J Am Acad Orthop Surg. 2009;17(9):572\u201381. https:\/\/doi.org\/10.5435\/00124635-200909000-00004.","journal-title":"J Am Acad Orthop Surg"},{"issue":"2","key":"7954_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2010.01.032","volume":"64","author":"M Ledoux","year":"2011","unstructured":"Ledoux M, Beauchet A, Fermanian C, et al. A case-control study of cutaneous signs in adult patients with Marfan disease: diagnostic value of striae. J Am Acad Dermatol. 2011;64(2):290\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2010.01.032.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"7954_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/genes13010023","volume":"13","author":"BJ Landis","year":"2021","unstructured":"Landis BJ, Vujakovich CE, Elmore LR, et al. An Emergent Nexus between Striae and Thoracic Aortic Dissection. Genes (Basel). 2021;13(1):23. https:\/\/doi.org\/10.3390\/genes13010023.","journal-title":"Genes (Basel)"},{"issue":"2","key":"7954_CR23","doi-asserted-by":"publisher","first-page":"263300402110557","DOI":"10.1177\/26330040211055738","volume":"9","author":"H Akram","year":"2021","unstructured":"Akram H, Aragon-Martin JA, Chandra A. Marfan syndrome and the eye clinic: from diagnosis to management. Ther Adv Rare Dis. 2021;9(2):26330040211055738. https:\/\/doi.org\/10.1177\/26330040211055738.","journal-title":"Ther Adv Rare Dis"},{"issue":"7","key":"7954_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/jmg.2009.072785","volume":"47","author":"BL Loeys","year":"2010","unstructured":"Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476\u201385. https:\/\/doi.org\/10.1136\/jmg.2009.072785.","journal-title":"J Med Genet"},{"key":"7954_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/TACG.S60472","volume":"8","author":"Y von Kodolitsch","year":"2015","unstructured":"von Kodolitsch Y, De Backer J, Sch\u00fcler H, et al. Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. Appl Clin Genet. 2015;8:137\u201355. https:\/\/doi.org\/10.2147\/TACG.S60472.","journal-title":"Appl Clin Genet"},{"key":"7954_CR26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/humu.24283","volume":"42","author":"ZX Chen","year":"2021","unstructured":"Chen ZX, Chen TH, Zhang M, et al. Correlation between FBN1 mutations and ocular features with ectopia lentis in the setting of Marfan syndrome and related fibrillinopathies. Hum Mutat. 2021;42:1637\u201347. https:\/\/doi.org\/10.1002\/humu.24283.","journal-title":"Hum Mutat"},{"key":"7954_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/s41436-021-01132-x","volume":"23","author":"P Arnaud","year":"2021","unstructured":"Arnaud P, Milleron O, Hanna N, et al. Clinical relevance of genotype\u2013phenotype correlations beyond vascular events in a cohort study of 1500 Marfan syndrome patients with FBN1 pathogenic variants. Genet Med. 2021;23:1296\u201304. https:\/\/doi.org\/10.1038\/s41436-021-01132-x.","journal-title":"Genet Med"},{"key":"7954_CR28","doi-asserted-by":"publisher","first-page":"943083","DOI":"10.3389\/fgene.2022.943083","volume":"13","author":"Z-U Chen","year":"2022","unstructured":"Chen Z-U, Jia W-N, Jiang Y-X. Genotype-phenotype correlations of marfan syndrome and related fibrillinopathies: Phenomenon and molecular relevance. Front Genet. 2022;13:943083. https:\/\/doi.org\/10.3389\/fgene.2022.943083.","journal-title":"Front Genet"},{"issue":"1","key":"7954_CR29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1186\/s12887-023-04357-8","volume":"23","author":"A Kemezyte","year":"2023","unstructured":"Kemezyte A, Gegieckiene R, Burnyte B. Genotype-phenotype spectrum and prognosis of early-onset Marfan syndrome. BMC Pediatr. 2023;23(1):539. https:\/\/doi.org\/10.1186\/s12887-023-04357-8.","journal-title":"BMC Pediatr"},{"key":"7954_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2025-326810","author":"S Korukonda","year":"2025","unstructured":"Korukonda S, Byers PH, Kovuri P, et al. Genotype-aortic phenotype correlations in Marfan syndrome: a systematic review and meta-analysis of Fibrillin-1 variants. Heart. 2025. https:\/\/doi.org\/10.1136\/heartjnl-2025-326810.","journal-title":"Heart"},{"key":"7954_CR31","doi-asserted-by":"publisher","unstructured":"Goldfinge JZ, Preiss LR, Devereux RB et al. Marfan syndrome and quality of life in the GenTAC Registry. J Am College Cardiol. 2017;69(23):2821\u201330; https:\/\/doi.org\/10.1016\/j.jacc.2017.04.026","DOI":"10.1016\/j.jacc.2017.04.026"},{"key":"7954_CR32","unstructured":"the National Marfan Foundation. Quality of Life. 2026. https:\/\/marfan.org\/expectations\/quality-of-life\/. Acessed 07 Jul 2026."},{"issue":"3","key":"7954_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0039-1693663","volume":"8","author":"C Nielsen","year":"2019","unstructured":"Nielsen C, Ratiu I, Esfandiarei M, et al. A Review of Psychosocial Factors of Marfan Syndrome: Adolescents, Adults, Families, and Providers. J Pediatr Genet. 2019;8(3):109\u2013. https:\/\/doi.org\/10.1055\/s-0039-1693663. 22.","journal-title":"J Pediatr Genet"},{"issue":"2","key":"7954_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.a.61441","volume":"182","author":"TT Vanem","year":"2020","unstructured":"Vanem TT, B\u00f6ker T, Sandvik GF, et al. Marfan syndrome: evolving organ manifestations-A 10-year follow-up study. Am J Med Genet A. 2020;182(2):397\u2013408. https:\/\/doi.org\/10.1002\/ajmg.a.61441.","journal-title":"Am J Med Genet A"},{"key":"7954_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.amjcard.2022.04.012","volume":"175","author":"B Connor","year":"2022","unstructured":"Connor B, Algaze CA, Narkevi\u010di\u016bt\u0117 A, et al. Prevalence and Outcomes of Primary Left Ventricular Dysfunction in Marfan Syndrome. Am J Cardiol. 2022;175:119\u201326. https:\/\/doi.org\/10.1016\/j.amjcard.2022.04.012.","journal-title":"Am J Cardiol"},{"issue":"6","key":"7954_CR36","doi-asserted-by":"publisher","first-page":"104503","DOI":"10.1016\/j.ejmg.2022.104503","volume":"65","author":"A Demolder","year":"2022","unstructured":"Demolder A, Bianco L, Caruana M, et al. Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: An international retrospective cohort study. Eur J Med Genet. 2022;65(6):104503. https:\/\/doi.org\/10.1016\/j.ejmg.2022.104503.","journal-title":"Eur J Med Genet"},{"issue":"1","key":"7954_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/jmedgenet-2021-108186","volume":"60","author":"Y Taniguchi","year":"2023","unstructured":"Taniguchi Y, Takeda N, Inuzuka R, et al. Impact of pathogenic FBN1 variant types on the development of severe scoliosis in patients with Marfan syndrome. J Med Genet. 2023;60(1):74\u201380. https:\/\/doi.org\/10.1136\/jmedgenet-2021-108186.","journal-title":"J Med Genet"},{"issue":"5","key":"7954_CR38","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/jbmr.4258","volume":"36","author":"L Folkestad","year":"2021","unstructured":"Folkestad L, Stochholm K, Groth K, et al. Fracture Rates and Fracture Risk in Patients With Marfan Syndrome: A Nationwide Register-Based Cohort Study. J Bone Mineral Res. 2021;36(5):901\u20139. https:\/\/doi.org\/10.1002\/jbmr.4258.","journal-title":"J Bone Mineral Res"},{"issue":"1","key":"7954_CR39","doi-asserted-by":"publisher","first-page":"e000942","DOI":"10.1136\/bmjresp-2021-000942","volume":"8","author":"M Sowho","year":"2021","unstructured":"Sowho M, MacCarrick G, Dietz H, et al. Association of sleep apnoea risk and aortic enlargement in Marfan syndrome. BMJ Open Resp Res. 2021;8(1):e000942. https:\/\/doi.org\/10.1136\/bmjresp-2021-000942.","journal-title":"BMJ Open Resp Res"},{"issue":"8","key":"7954_CR40","doi-asserted-by":"publisher","first-page":"e805","DOI":"10.1002\/mgg3.805","volume":"7","author":"L Mui\u00f1o-Mosquera","year":"2019","unstructured":"Mui\u00f1o-Mosquera L, Bauters F, Dhondt K, et al. Sleep apnea and the impact on cardiovascular risk in patients with Marfan syndrome. Mol Genet Genomic Med. 2019;7(8):e805. https:\/\/doi.org\/10.1002\/mgg3.805.","journal-title":"Mol Genet Genomic Med"},{"issue":"4","key":"7954_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0828-282x(10)70370-6","volume":"26","author":"AT Yetman","year":"2010","unstructured":"Yetman AT, McCrindle BW. The prevalence and clinical impact of obesity in adults with Marfan syndrome. Can J Cardiol. 2010;26(4):137\u20139. https:\/\/doi.org\/10.1016\/s0828-282x(10)70370-6.","journal-title":"Can J Cardiol"},{"issue":"2","key":"7954_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/23969873221149848","volume":"8","author":"G Vornetti","year":"2023","unstructured":"Vornetti G, De Martino SRM, Baroni MC, et al. Prevalence of unruptured intracranial aneurysms in patients with Marfan syndrome: A cross-sectional study and meta-analysis. Eur Stroke J. 2023;8(2):501\u20137. https:\/\/doi.org\/10.1177\/23969873221149848.","journal-title":"Eur Stroke J"},{"issue":"3","key":"7954_CR43","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jvs.2023.05.004","volume":"78","author":"DJ Laczynski","year":"2023","unstructured":"Laczynski DJ, Dong S, Kalahasti V, et al. Prevalence of intracranial aneurysms in Marfan syndrome. J Vasc Surg. 2023;78(3):633\u20137. https:\/\/doi.org\/10.1016\/j.jvs.2023.05.004.","journal-title":"J Vasc Surg"},{"key":"7954_CR44","doi-asserted-by":"publisher","first-page":"e345","DOI":"10.1016\/j.wneu.2021.08.065","volume":"155","author":"RA Domingo","year":"2021","unstructured":"Domingo RA, Perez-Vega C, Tripathi S, et al. Intracranial Aneurysms in Patients with Marfan Syndrome: A Multicenter Propensity-Matched Analysis. World Neurosurg. 2021;155:e345\u201352. https:\/\/doi.org\/10.1016\/j.wneu.2021.08.065.","journal-title":"World Neurosurg"},{"issue":"1","key":"7954_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/STROKEAHA.120.032107","volume":"52","author":"JH Kim","year":"2021","unstructured":"Kim JH, Kim J, Song SW, et al. Intracranial Aneurysms Are Associated With Marfan Syndrome: Single Cohort Retrospective Study in 118 Patients Using Brain Imaging. Stroke. 2021;52(1):331\u20134. https:\/\/doi.org\/10.1161\/STROKEAHA.120.032107.","journal-title":"Stroke"},{"issue":"6","key":"7954_CR46","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/0333102412441091","volume":"32","author":"H Koppe","year":"2012","unstructured":"Koppe H, Vis JC, Gooiker DJ, et al. Aortic root pathology in Marfan syndrome increases the risk of migraine with aura. Cephalalgia. 2012;32(6):467\u201372. https:\/\/doi.org\/10.1177\/0333102412441091.","journal-title":"Cephalalgia"},{"issue":"3","key":"7954_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijcard.2008.05.037","volume":"136","author":"JC Vis","year":"2009","unstructured":"Vis JC, Timmermans J, Post MC, et al. Increased prevalence of migraine in Marfan syndrome. Int J Cardiol. 2009;136(3):330\u201334. https:\/\/doi.org\/10.1016\/j.ijcard.2008.05.037.","journal-title":"Int J Cardiol"},{"issue":"7","key":"7954_CR48","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s11136-015-1214-1","volume":"25","author":"G Velvin","year":"2016","unstructured":"Velvin G, Bathen T, Rand-Hendriksen S, Geirdal A. Satisfaction with life in adults with Marfan syndrome (MFS): associations with health-related consequences of MFS, pain, fatigue, and demographic factors. Qual Life Res. 2016;25(7):1779\u201390. https:\/\/doi.org\/10.1007\/s11136-015-1214-1.","journal-title":"Qual Life Res"},{"issue":"6","key":"7954_CR49","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cge.12699","volume":"89","author":"G Velvin","year":"2016","unstructured":"Velvin G, Bathen T, Rand-Hendriksen S, Geirdal A. Systematic review of chronic pain in persons with Marfan syndrome. Clin Genet. 2016;89(6):647\u201358. https:\/\/doi.org\/10.1111\/cge.12699.","journal-title":"Clin Genet"},{"issue":"5","key":"7954_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/cge.14211","volume":"102","author":"MM van Andel","year":"2022","unstructured":"van Andel MM, Graaumans K, Groenink M, et al. A cross-sectional study on fatigue, anxiety, and symptoms of depression and their relation with medical status in adult patients with Marfan syndrome. Psychological consequences in Marfan syndrome. Clin Genet. 2022;102(5):404\u201313. https:\/\/doi.org\/10.1111\/cge.14211.","journal-title":"Clin Genet"},{"issue":"2","key":"7954_CR51","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00018-016-2324-9","volume":"74","author":"GL Perrucci","year":"2017","unstructured":"Perrucci GL, Rurali E, Gowran A, et al. Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall. Cell Mol Life Sci. 2017;74(2):267\u201377. https:\/\/doi.org\/10.1007\/s00018-016-2324-9.","journal-title":"Cell Mol Life Sci"},{"key":"7954_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010128","author":"K Asano","year":"2022","unstructured":"Asano K, Cantalupo A, Sedes L, Ramirez F. Pathophysiology and therapeutics of thoracic aortic aneurysm in Marfan syndrome. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12010128.","journal-title":"Biomolecules"},{"issue":"7","key":"7954_CR53","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/bph.15694","volume":"179","author":"M Toral","year":"2022","unstructured":"Toral M, de la Fuente-Alonso A, Campanero MR, et al. The NO signalling pathway in aortic aneurysm and dissection. Br J Pharmacol. 2022;179(7):1287\u2013303. https:\/\/doi.org\/10.1111\/bph.15694.","journal-title":"Br J Pharmacol"},{"key":"7954_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2023.107215","volume":"53","author":"S Seeburun","year":"2023","unstructured":"Seeburun S, Wu S, Hemani D, et al. Insights into elastic fiber fragmentation: mechanisms and treatment of aortic aneurysm in Marfan syndrome. Vascul Pharmacol. 2023;53:107215. https:\/\/doi.org\/10.1016\/j.vph.2023.107215.","journal-title":"Vascul Pharmacol"},{"key":"7954_CR55","doi-asserted-by":"publisher","first-page":"1463318","DOI":"10.3389\/fgene.2024.1463318","volume":"15","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Jia P, Feng X, Zhang D. Marfan syndrome: insights from animal models. Front Genet. 2025;15:1463318. https:\/\/doi.org\/10.3389\/fgene.2024.1463318.","journal-title":"Front Genet"},{"key":"7954_CR56","doi-asserted-by":"publisher","first-page":"cvag114","DOI":"10.1093\/cvr\/cvag114","volume":"15","author":"JD Humphrey","year":"2026","unstructured":"Humphrey JD, Milewicz DM. The aorta in Marfan syndrome - from molecular mechanisms to mechanobiological dysfunction. Cardiovasc Res. 2026;15:cvag114. https:\/\/doi.org\/10.1093\/cvr\/cvag114.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"7954_CR57","doi-asserted-by":"publisher","first-page":"H1081","DOI":"10.1152\/ajpheart.00770.2015","volume":"310","author":"Y Onetti","year":"2016","unstructured":"Onetti Y, Meirelles T, Dantas AP, et al. NADPH oxidase 4 attenuates cerebral artery changes during the progression of Marfan syndrome. Am J Physiol Heart Circ Physiol. 2016;310(9):H1081\u201390. https:\/\/doi.org\/10.1152\/ajpheart.00770.2015.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"7954_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.freeradbiomed.2018.02.023","volume":"118","author":"F Jim\u00e9nez-Altay\u00f3","year":"2018","unstructured":"Jim\u00e9nez-Altay\u00f3 F, Meirelles T, Crosas-Molist E, et al. Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm. Free Rad Biol Med. 2018;118:44\u201358. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.02.023.","journal-title":"Free Rad Biol Med"},{"key":"7954_CR59","doi-asserted-by":"publisher","first-page":"101757","DOI":"10.1016\/j.redox.2020.101757","volume":"38","author":"K Huang","year":"2021","unstructured":"Huang K, Wang Y, Siu KL, et al. Targeting feed-forward signaling of TGF\u03b2\/NOX4\/DHFR\/eNOS uncoupling\/TGF\u03b2 axis with anti-TGF\u03b2 and folic acid attenuates formation of aortic aneurysms: Novel mechanisms and therapeutics. Redox Biol. 2021;38:101757. https:\/\/doi.org\/10.1016\/j.redox.2020.101757.","journal-title":"Redox Biol"},{"key":"7954_CR60","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.freeradbiomed.2022.11.001","volume":"193","author":"I Rodr\u00edguez-Rovira","year":"2022","unstructured":"Rodr\u00edguez-Rovira I, Arce C, De Rycke, et al. Allopurinol blocks aortic aneurysm in a mouse model of Marfan syndrome via reducing aortic oxidative stress. Free Rad Biol Med. 2022;193:538\u201350. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2022.11.001.","journal-title":"Free Rad Biol Med"},{"issue":"3","key":"7954_CR61","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1161\/ATVBAHA.124.321527","volume":"45","author":"H Yagi","year":"2025","unstructured":"Yagi H, Akazawa H, Liu Q, Yamamoto K, et al. XOR-Derived ROS in Tie2-Lineage Cells Including Endothelial Cells Promotes Aortic Aneurysm Progression in Marfan Syndrome. Arterioscler Thromb Vasc Biol. 2025;45(3):e63\u201377. https:\/\/doi.org\/10.1161\/ATVBAHA.124.321527.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"7954_CR62","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/CIRCULATIONAHA.120.051171","volume":"143","author":"J Oller","year":"2021","unstructured":"Oller J, Gaband\u00e9-Rodr\u00edguez E, Ruiz-Rodr\u00edguez MJ, et al. Extracellular tuning of mitochondrial respiration leads to aortic aneurysm. Circulation. 2021;143(21):2091\u2013109. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051171.","journal-title":"Circulation"},{"issue":"8","key":"7954_CR63","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/cells14080618","volume":"14","author":"D Marcos-R\u00edos","year":"2025","unstructured":"Marcos-R\u00edos D, Rochano-Ortiz A, San Sebasti\u00e1n-Jaraba I, et al. Mitochondrial Dysfunction: A New Hallmark in Hereditable Thoracic Aortic Aneurysm Development. Cells. 2025;14(8):618. https:\/\/doi.org\/10.3390\/cells14080618.","journal-title":"Cells"},{"issue":"2","key":"7954_CR64","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/cvr\/cvaf248","volume":"122","author":"D Mehrkens","year":"2026","unstructured":"Mehrkens D, Dohr J, Nettersheim FS, et al. Myeloperoxidase aggravates thoracic aortic aneurysm formation in Marfan disease. Cardiovasc Res. 2026;122(2):230\u2013. https:\/\/doi.org\/10.1093\/cvr\/cvaf248. 44.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"7954_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/heartjnl-2024-324343","volume":"111","author":"MM van Andel","year":"2024","unstructured":"van Andel MM, Bosshardt D, Schrauben EM, et al. Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial. Heart. 2024;111(1):11\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2024-324343.","journal-title":"Heart"},{"issue":"8","key":"7954_CR66","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1161\/ATVBAHA.116.307841","volume":"36","author":"S Hibender","year":"2016","unstructured":"Hibender S, Franken R, Van Roomen C, et al. Resveratrol inhibits aortic root dilatation in the Fbn1 C1039G\/+ Marfan mouse model. Arterioscler Thromb Vasc Biol. 2016;36(8):1618\u201326. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307841.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"7954_CR67","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3390\/ijms20051122","volume":"20","author":"MM van Andel","year":"2019","unstructured":"van Andel MM, Groenink M, Zwinderman AH, et al. The potential beneficial effects of resveratrol on cardiovascular complications in Marfan syndrome patients\u2013insights from rodent-based animal studies. Int J Mol Sci. 2019;20(5):1122. https:\/\/doi.org\/10.3390\/ijms20051122.","journal-title":"Int J Mol Sci"},{"key":"7954_CR68","doi-asserted-by":"publisher","unstructured":"Mieremet A, van der Stoel M, Li S, et al. Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol. Scie Rep. 2022;12(1). https:\/\/doi.org\/10.1038\/s41598-022-26662-5.","DOI":"10.1038\/s41598-022-26662-5"},{"key":"7954_CR69","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/antiox9101013","volume":"9","author":"G Egea","year":"2020","unstructured":"Egea G, Jim\u00e9nez-Altay\u00f3 F, Campuzano V. Reactive Oxygen Species and Oxidative Stress in Pathogenesis and Progression of Genetic Diseases of the Connective Tissue. Antioxid (Basel). 2020;9:1013. https:\/\/doi.org\/10.3390\/antiox9101013.","journal-title":"Antioxid (Basel)"},{"issue":"1","key":"7954_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/13510002.2021.1899473","volume":"26","author":"SS Portelli","year":"2021","unstructured":"Portelli SS, Hambly BD, Jeremy RW, Robertson EN. Oxidative stress in genetically triggered thoracic aortic aneurysm: role in pathogenesis and therapeutic opportunities. Redox Rep. 2021;26(1):45\u201352. https:\/\/doi.org\/10.1080\/13510002.2021.1899473.","journal-title":"Redox Rep"},{"issue":"9","key":"7954_CR71","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/biomedicines9091171","volume":"9","author":"J Rysz","year":"2021","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Rokicki R, Franczyk B. Oxidative Stress-Related Susceptibility to Aneurysm in Marfan\u2019s Syndrome. Biomedicines. 2021;9(9):1171. https:\/\/doi.org\/10.3390\/biomedicines9091171.","journal-title":"Biomedicines"},{"issue":"4","key":"7954_CR72","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3390\/ijms27041855","volume":"27","author":"S Krych","year":"2026","unstructured":"Krych S, Gniewek J, Kolbowicz M, et al. Oxidative Stress-Induced DNA Damage Response Pathways in Aortic Disease: Implications for Inflammation and Vascular Degeneration. Int J Mol Sci. 2026;27(4):1855. https:\/\/doi.org\/10.3390\/ijms27041855.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"7954_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1056\/NEJM197904053001406","volume":"300","author":"RE Pyeritz","year":"1979","unstructured":"Pyeritz RE, McKusick VA. The Marfan syndrome: diagnosis and management. N Engl J Med. 1979;300(14):772\u20137. https:\/\/doi.org\/10.1056\/NEJM197904053001406.","journal-title":"N Engl J Med"},{"issue":"13","key":"7954_CR74","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/diagnostics13132284","volume":"13","author":"S Marelli","year":"2023","unstructured":"Marelli S, Micaglio E, Taurino J, et al. Marfan Syndrome: Enhanced Diagnostic Tools and Follow-up Management Strategies. Diagnostics. 2023;13(13):2284. https:\/\/doi.org\/10.3390\/diagnostics13132284.","journal-title":"Diagnostics"},{"key":"7954_CR75","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.1093\/ehjci\/jead024","volume":"24","author":"A Evangelista","year":"2023","unstructured":"Evangelista A, Sitges M, Jondeau G, et al. Multimodality imaging in thoracic aortic diseases: a clinical consensus statement from the European Association of Cardiovascular Imaging and the European Society of Cardiology working group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imag. 2023;24:E65\u201385. https:\/\/doi.org\/10.1093\/ehjci\/jead024.","journal-title":"Eur Heart J Cardiovasc Imag"},{"issue":"4","key":"7954_CR76","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/14779072.2019.1585807","volume":"17","author":"CGE Thijssen","year":"2019","unstructured":"Thijssen CGE, Bons LR, G\u00f6kalp AL, et al. Exercise and sports participation in patients with thoracic aortic disease: a review. Expert Rev Cardiovasc Ther. 2019;17(4):251\u201366. https:\/\/doi.org\/10.1080\/14779072.2019.1585807.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"9","key":"7954_CR77","doi-asserted-by":"publisher","first-page":"e006438","DOI":"10.1161\/JAHA.117.006438","volume":"6","author":"A Mas-Stachurska","year":"2017","unstructured":"Mas-Stachurska A, Siegert AM, Batlle M, et al. Cardiovascular Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an Animal Model. J Am Heart Assoc. 2017;6(9):e006438. https:\/\/doi.org\/10.1161\/JAHA.117.006438.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"7954_CR78","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/japplphysiol.00132.2017","volume":"123","author":"C Gibson","year":"2018","unstructured":"Gibson C, Nielsen C, Alex R, et al. Mild aerobic exercise blocks elastin fiber fragmentation and aortic dilatation in a mouse model of Marfan syndrome associated aortic aneurysm. J Appl Physiol (1985). 2018;123(1):147\u201360. https:\/\/doi.org\/10.1152\/japplphysiol.00132.2017.","journal-title":"J Appl Physiol (1985)"},{"issue":"22","key":"7954_CR79","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1056\/nejmoa1404731","volume":"371","author":"RV Lacro","year":"2014","unstructured":"Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus Losartan in Children and Young Adults with Marfan\u2019s Syndrome. New Engl J Med. 2014;371(22):2061\u201371. https:\/\/doi.org\/10.1056\/nejmoa1404731.","journal-title":"New Engl J Med"},{"key":"7954_CR80","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1161\/CIR.0000000000000243","volume":"132","author":"AC Braverman","year":"2015","unstructured":"Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 7: Aortic Diseases, Including Marfan Syndrome: A Scientific Statement from the American Heart Association and American College of Cardiology. Circulation. 2015;132:e303\u20139. https:\/\/doi.org\/10.1161\/CIR.0000000000000243.","journal-title":"Circulation"},{"issue":"2","key":"7954_CR81","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1358863X251406525","volume":"31","author":"G Maciel Oliveira","year":"2026","unstructured":"Maciel Oliveira G, Junqueira Franco Stoppe J, Duarte de Andrade SM, et al. What\u2019s new about angiotensin receptor blocker (ARB) therapy for Marfan syndrome: A narrative review. Vasc Med. 2026;31(2):219\u2013. https:\/\/doi.org\/10.1177\/1358863X251406525. 31.","journal-title":"Vasc Med"},{"key":"7954_CR82","doi-asserted-by":"publisher","unstructured":"Silverman DI, Burton KJ, Gray J et al. (1995). Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157\u201360.\u00a0https:\/\/doi.org\/10.1016\/s0002-9149(00)80066-1","DOI":"10.1016\/s0002-9149(00)80066-1"},{"issue":"3","key":"7954_CR83","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/01.CIR.91.3.728","volume":"91","author":"R Finkbohner","year":"1995","unstructured":"Finkbohner R, Johnston D, Crawford ES, et al. Long-term survival and complications after aortic aneurysm repair in Marfan syndrome. Circulation. 1995;91(3):728\u201333. https:\/\/doi.org\/10.1161\/01.CIR.91.3.728.","journal-title":"Circulation"},{"issue":"17","key":"7954_CR84","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJM199904293401702","volume":"340","author":"VL Gott","year":"1999","unstructured":"Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan\u2019s syndrome. New Engl J Med. 1999;340(17):1307\u201313. https:\/\/doi.org\/10.1056\/NEJM199904293401702.","journal-title":"New Engl J Med"},{"key":"7954_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/CIR.0b013e3181d4739e","volume":"121","author":"LF Hiratzka","year":"2010","unstructured":"Hiratzka LF, Bakris GL, Beckman JA, et al. ACCF\/AHA\/AATS\/ACR\/ASA\/SCA\/SCAI\/SIR\/STS\/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: Executive summary: A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, American association for Thoracic Surgery, American College of Radiology, American Stroke Association. Circulation. 2010;121:13. https:\/\/doi.org\/10.1161\/CIR.0b013e3181d4739e.","journal-title":"Circulation"},{"issue":"6","key":"7954_CR86","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.athoracsur.2019.08.096","volume":"109","author":"C Mart\u00edn","year":"2020","unstructured":"Mart\u00edn C, Evangelista A, Serrano-Fiz S, et al. Aortic complications in Marfan syndrome: should we anticipate preventive aortic root surgery? Ann Thorac Surg. 2020;109(6):1850\u20137. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.08.096.","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"7954_CR87","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jtcvs.2018.09.148","volume":"157","author":"CD Fraser","year":"2019","unstructured":"Fraser CD, Liu RH, Zhou X, et al. Valve-sparing aortic root replacement in children: Outcomes from 100 consecutive cases. J Thorac Cardiovasc Surg. 2019;157(3):1100\u201309. https:\/\/doi.org\/10.1016\/j.jtcvs.2018.09.148.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"11","key":"7954_CR88","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1161\/CIR.0000000000001265","volume":"150","author":"SA Morris","year":"2024","unstructured":"Morris SA, Flyer JN, Yetman AT, et al. Cardiovascular Management of Aortopathy in Children: A Scientific Statement From the American Heart Association. Circulation. 2024;150(11):e228\u201354. https:\/\/doi.org\/10.1161\/CIR.0000000000001265.","journal-title":"Circulation"},{"key":"7954_CR89","doi-asserted-by":"publisher","first-page":"ezad426","DOI":"10.1093\/ejcts\/ezad426","volume":"65","author":"M Czerny","year":"2024","unstructured":"Czerny M, Grabenw\u00f6ger M, Berger T, et al. EACTS\/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg. 2024;65:ezad426.","journal-title":"Eur J Cardiothorac Surg"},{"key":"7954_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.avsg.2022.04.049","volume":"94","author":"LM Steinmetz","year":"2023","unstructured":"Steinmetz LM, Coselli JS. Endovascular Repair in Patients with Marfan Syndrome: Concerns Amid Controversy. Ann Vasc Surg. 2023;94:1\u20137. https:\/\/doi.org\/10.1016\/j.avsg.2022.04.049.","journal-title":"Ann Vasc Surg"},{"issue":"1","key":"7954_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.23736\/S0021-9509.22.12441-9","volume":"64","author":"Y Yokoyama","year":"2023","unstructured":"Yokoyama Y, Tsukagoshi J, Hamlin S, et al. Endovascular therapy for Stanford B aortic dissection for patients with Marfan Syndrome: systematic review and meta-analysis. J Cardiovasc Surg (Torino). 2023;64(1):41\u20137. https:\/\/doi.org\/10.23736\/S0021-9509.22.12441-9.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"7954_CR92","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/heartjnl-2013-304913","volume":"100","author":"T Treasure","year":"2014","unstructured":"Treasure T, Takkenberg JJM, Golesworthy T, et al. Personalised external aortic root s9-year (PEARS) in Marfan syndrome: analysis of 1\u20139 year outcomes by intention- to- treat in a cohort of the first 30 consecutive patients to receive a novel tissue and valve- conserving procedure, compared with the published results of aortic root replacement. Heart. 2014;100:969\u201375. https:\/\/doi.org\/10.1136\/heartjnl-2013-304913.","journal-title":"Heart"},{"key":"7954_CR93","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1136\/heartjnl-2021-319300","volume":"107","author":"L Van Hoof","year":"2021","unstructured":"Van Hoof L, Rega F, Golesworthy T, et al. Personalised external aortic root support for elective treatment of aortic root dilation in 200 patients. Heart. 2021;107:1790\u20135. https:\/\/doi.org\/10.1136\/heartjnl-2021-319300.","journal-title":"Heart"},{"issue":"1","key":"7954_CR94","doi-asserted-by":"publisher","first-page":"iyad189","DOI":"10.1093\/genetics\/iyad189","volume":"226","author":"KM Summers","year":"2024","unstructured":"Summers KM. Genetic models of fibrillinopathies. Genetics. 2024;226(1):iyad189. https:\/\/doi.org\/10.1093\/genetics\/iyad189.","journal-title":"Genetics"},{"issue":"7","key":"7954_CR95","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/jamacardio.2019.1176","volume":"4","author":"MA Hofmann Bowman","year":"2019","unstructured":"Hofmann Bowman MA, Eagle KA, Milewicz DM. Update on Clinical Trials of Losartan with and Without \u03b2-Blockers to Block Aneurysm Growth in Patients with Marfan Syndrome: A Review. JAMA Cardiol. 2019;4(7):702\u20137. https:\/\/doi.org\/10.1001\/jamacardio.2019.1176.","journal-title":"JAMA Cardiol"},{"key":"7954_CR96","doi-asserted-by":"publisher","unstructured":"Van Den Heuvel LJF, Peeters S, Meester J, et al. An exploration of alternative therapeutic targets for aortic disease in Marfan syndrome. Drug Discov Today. 2024;29(7). https:\/\/doi.org\/10.1016\/j.drudis.2024.104023.","DOI":"10.1016\/j.drudis.2024.104023"},{"key":"7954_CR97","doi-asserted-by":"publisher","first-page":"7365","DOI":"10.2147\/DDDT.S523571","volume":"19","author":"X Feng","year":"2025","unstructured":"Feng X, Qu C, Jia P, Zhang DD. Therapeutic Opportunities of Marfan Syndrome: Current Perspectives. Drug Des Devel Ther. 2025;19:7365\u201379. https:\/\/doi.org\/10.2147\/DDDT.S523571.","journal-title":"Drug Des Devel Ther"},{"issue":"5770","key":"7954_CR98","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1126\/science.1124287","volume":"312","author":"JP Habashi","year":"2006","unstructured":"Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117\u201321. https:\/\/doi.org\/10.1126\/science.1124287.","journal-title":"Science"},{"key":"7954_CR99","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","volume":"358","author":"BS Brooke","year":"2008","unstructured":"Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome. N Engl J Med. 2008;358:2787\u201395. https:\/\/doi.org\/10.1056\/NEJMoa0706585.","journal-title":"N Engl J Med"},{"issue":"19","key":"7954_CR100","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","volume":"330","author":"J Shores","year":"1994","unstructured":"Shores J, Berger KR, Murphy E, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan\u2019s syndrome. New Engl J Med. 1994;330(19):1335\u201341. https:\/\/doi.org\/10.1056\/NEJM199405123301902.","journal-title":"New Engl J Med"},{"issue":"1","key":"7954_CR101","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cjca.2015.11.003","volume":"32","author":"MN Singh","year":"2016","unstructured":"Singh MN, Lacro LV. Recent Clinical Drug Trials Evidence in Marfan Syndrome and Clinical Implications. Can J Cardiol. 2016;32(1):66\u201377. https:\/\/doi.org\/10.1016\/j.cjca.2015.11.003.","journal-title":"Can J Cardiol"},{"issue":"10","key":"7954_CR102","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMc1500128","volume":"372","author":"RV Lacro","year":"2015","unstructured":"Lacro RV, Dietz HC, Mahony L. Atenolol versus Losartan in Marfan\u2019s Syndrome. N Engl J Med. 2015;372(10):980\u20131. https:\/\/doi.org\/10.1056\/NEJMc1500128.","journal-title":"N Engl J Med"},{"issue":"12","key":"7954_CR103","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","volume":"37","author":"A Forteza","year":"2016","unstructured":"Forteza A, Evangelista A, S\u00e1nchez V, et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial. Eur Heart J. 2016;37(12):978\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehv575.","journal-title":"Eur Heart J"},{"issue":"14","key":"7954_CR104","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jacc.2018.07.052","volume":"72","author":"G Teixido-Tura","year":"2018","unstructured":"Teixido-Tura G, Forteza A, Rodr\u00edguez-Palomares J, et al. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. J Am Coll Cardiol. 2018;72(14):1613\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.052.","journal-title":"J Am Coll Cardiol"},{"issue":"45","key":"7954_CR105","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","volume":"34","author":"M Groenink","year":"2013","unstructured":"Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34(45):3491\u2013500. https:\/\/doi.org\/10.1093\/eurheartj\/eht334.","journal-title":"Eur Heart J"},{"key":"7954_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","volume":"88","author":"HH Chiu","year":"2013","unstructured":"Chiu HH, Wu MH, Wang JK, et al. Losartan added to \u03b2-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc. 2013;88:271\u20136. https:\/\/doi.org\/10.1016\/j.mayocp.2012.11.005.","journal-title":"Mayo Clin Proc"},{"issue":"32","key":"7954_CR107","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","volume":"36","author":"O Milleron","year":"2015","unstructured":"Milleron O, Arnoult F, Ropers J, et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2015;36(32):2160\u20136. https:\/\/doi.org\/10.1093\/eurheartj\/ehv151.","journal-title":"Eur Heart J"},{"issue":"10355","key":"7954_CR108","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(22)01534-3","volume":"400","author":"A Pitcher","year":"2022","unstructured":"Pitcher A, Spata E, Emberson J, et al. Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials. Lancet. 2022;400(10355):822\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(22)01534-3.","journal-title":"Lancet"},{"key":"7954_CR109","doi-asserted-by":"publisher","first-page":"133318","DOI":"10.1016\/j.ijcard.2025.133318","volume":"433","author":"PJMH Saraber","year":"2025","unstructured":"Saraber PJMH, Bica LC, Reesink KD, et al. The clinical relevance of the decelerating effect of angiotensin receptor blockers on aortic growth in Marfan patients; a Bayesian perspective. Int J Cardiol. 2025;433:133318. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133318.","journal-title":"Int J Cardiol"},{"key":"7954_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2025.107494","volume":"159","author":"LH Tanriverdi","year":"2025","unstructured":"Tanriverdi LH, Barrett A, Kalyanasundaram A, et al. Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: a systematic review and meta-analysis of randomized controlled trials. Vascul Pharmacol. 2025;159:107494. https:\/\/doi.org\/10.1016\/j.vph.2025.107494.","journal-title":"Vascul Pharmacol"},{"key":"7954_CR111","doi-asserted-by":"publisher","first-page":"e08648","DOI":"10.7554\/eLife.08648","volume":"4","author":"JJ Doyle","year":"2015","unstructured":"Doyle JJ, Doyle AJ, Wilson NK, et al. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. eLife. 2015;4:e08648. https:\/\/doi.org\/10.7554\/eLife.08648.","journal-title":"eLife"},{"issue":"2","key":"7954_CR112","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/CIRCGENETICS.114.000950","volume":"8","author":"R Franken","year":"2015","unstructured":"Franken R, Den Hartog AW, Radonic T, et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ Cardiovasc Genet. 2015;8(2):383\u20138. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000950.","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"7954_CR113","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.gim.2021.12.015","volume":"24","author":"JAN Meester","year":"2022","unstructured":"Meester JAN, Peeters S, Van Den Heuvel L, et al. Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort. Genet Med. 2022;24(5):1045\u201353. https:\/\/doi.org\/10.1016\/j.gim.2021.12.015.","journal-title":"Genet Med"},{"issue":"6","key":"7954_CR114","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/CIRCRESAHA.115.307130","volume":"118","author":"DC Guo","year":"2016","unstructured":"Guo DC, Regalado ES, Gong L, et al. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ Res. 2016;118(6):928\u201334. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.307130.","journal-title":"Circ Res"},{"key":"7954_CR115","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2125.2006.02785.x","volume":"62","author":"J Dawson","year":"2006","unstructured":"Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006;62:633\u201344. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02785.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"7954_CR116","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.651117.","journal-title":"Circulation"},{"issue":"1","key":"7954_CR117","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szab\u00f3 C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Reviews. 2006;58(1):87\u2013114. https:\/\/doi.org\/10.1124\/pr.58.1.6.","journal-title":"Pharmacol Reviews"},{"key":"7954_CR118","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, et al. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623\u201344. https:\/\/doi.org\/10.2165\/00003088-200746080-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"7954_CR119","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CRD.0b013e318229a908","volume":"19","author":"A Kelkar","year":"2011","unstructured":"Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev. 2011;19(6):265\u2013. https:\/\/doi.org\/10.1097\/CRD.0b013e318229a908. 71.","journal-title":"Cardiol Rev"},{"key":"7954_CR120","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/17425255.2017.1269745","volume":"13","author":"RO Day","year":"2017","unstructured":"Day RO, Kannangara DRW, Stocker SL, et al. Allopurinol: insights from studies of dose\u2013response relationships. Expert Opin Drug Metabol Toxicol. 2017;13:449\u201362. https:\/\/doi.org\/10.1080\/17425255.2017.1269745.","journal-title":"Expert Opin Drug Metabol Toxicol"},{"key":"7954_CR121","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/164_2020_383","volume":"264","author":"K Vickneson","year":"2021","unstructured":"Vickneson K, George J. Xanthine Oxidoreductase Inhibitors. Handb Experimental Pharmacol. 2021;264:205\u201328. https:\/\/doi.org\/10.1007\/164_2020_383.","journal-title":"Handb Experimental Pharmacol"},{"key":"7954_CR122","doi-asserted-by":"publisher","first-page":"102195","DOI":"10.1016\/j.redox.2021.102195","volume":"48","author":"L Polito","year":"2021","unstructured":"Polito L, Bortolotti M, Battelli MG, Bolognesi A. Xanthine oxidoreductase: A leading actor in cardiovascular disease drama. Redox Biol. 2021;48:102195. https:\/\/doi.org\/10.1016\/j.redox.2021.102195.","journal-title":"Redox Biol"},{"issue":"5","key":"7954_CR123","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/bcp.16005","volume":"90","author":"DFB Wright","year":"2024","unstructured":"Wright DFB, Hishe HZ, Stocker SL, et al. The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools). Br J Clin Pharmacol. 2024;90(5):1268\u201379. https:\/\/doi.org\/10.1111\/bcp.16005.","journal-title":"Br J Clin Pharmacol"},{"key":"7954_CR124","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","volume":"78","author":"D Bursill","year":"2019","unstructured":"Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis. 2019;78:1592\u2013600. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215933.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7954_CR125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47\u20136. https:\/\/doi.org\/10.1016\/0002-9343(84)90743-5.","journal-title":"Am J Med"},{"issue":"7517","key":"7954_CR126","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1136\/bmj.331.7517.623","volume":"331","author":"A Guti\u00e9rrez-Mac\u00edas","year":"2005","unstructured":"Guti\u00e9rrez-Mac\u00edas A, Lizarralde-Palacios E, Mart\u00ednez-Odriozola P, Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ. 2005;331(7517):623\u20134. https:\/\/doi.org\/10.1136\/bmj.331.7517.623.","journal-title":"BMJ"},{"issue":"8","key":"7954_CR127","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336. https:\/\/doi.org\/10.1002\/art.34488.","journal-title":"Arthritis Rheum"},{"key":"7954_CR128","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64654","author":"KM Dillman","year":"2024","unstructured":"Dillman KM, Hawkins A, Ragland AR, et al. Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.64654.","journal-title":"Cureus"},{"issue":"6","key":"7954_CR129","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00701.x","volume":"15","author":"V Agarwal","year":"2013","unstructured":"Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(6):435\u2013. https:\/\/doi.org\/10.1111\/j.1751-7176.2012.00701.x. 42.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"7954_CR130","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1755-5922.12215","volume":"34","author":"W Xin","year":"2016","unstructured":"Xin W, Mi S, Lin Z. Allopurinol therapy improves vascular endothelial function in subjects at risk for cardiovascular diseases: a meta-analysis of randomized controlled trials. Cardiovasc Ther. 2016;34(6):441\u20139. https:\/\/doi.org\/10.1111\/1755-5922.12215.","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"7954_CR131","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12432","volume":"36","author":"MM Alem","year":"2018","unstructured":"Alem MM. Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018;36(4):e12432. https:\/\/doi.org\/10.1111\/1755-5922.12432.","journal-title":"Cardiovasc Ther"},{"issue":"2","key":"7954_CR132","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1161\/01.cir.0000022140.61460.1d","volume":"106","author":"CAJ Farquharson","year":"2002","unstructured":"Farquharson CAJ, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106(2):221. https:\/\/doi.org\/10.1161\/01.cir.0000022140.61460.1d. 6.","journal-title":"Circulation"},{"key":"7954_CR133","doi-asserted-by":"publisher","first-page":"639392","DOI":"10.3389\/fcvm.2021.639392","volume":"8","author":"H Xu","year":"2021","unstructured":"Xu H, Liu Y, Meng L, Wang L, Liu D. Effect of Uric Acid-Lowering Agents on Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Front Cardiovasc Med. 2021;8:639392. https:\/\/doi.org\/10.3389\/fcvm.2021.639392.","journal-title":"Front Cardiovasc Med"},{"issue":"9732","key":"7954_CR134","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Noman","year":"2010","unstructured":"Noman A, Ang DSC, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo-controlled crossover trial. Lancet. 2010;375(9732):2161\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(10)60391-1.","journal-title":"Lancet"},{"issue":"18","key":"7954_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/ATTM4092","volume":"28","author":"IS McKenzie","year":"2024","unstructured":"McKenzie IS, Hawkey CJ, Ford I, et al. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. Health Technol Assess. 2024;28(18):1\u201355. https:\/\/doi.org\/10.3310\/ATTM4092.","journal-title":"Health Technol Assess"},{"issue":"12","key":"7954_CR136","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11886-024-02138-y","volume":"26","author":"Y Jamil","year":"2024","unstructured":"Jamil Y, Alameddine D, Iskandarani ME, et al. Cardiovascular Outcomes of Uric Acid Lowering Medications: A Meta-Analysis. Curr Cardiol Rep. 2024;26(12):1427\u201337. https:\/\/doi.org\/10.1007\/s11886-024-02138-y.","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"7954_CR137","doi-asserted-by":"publisher","first-page":"226","DOI":"10.14740\/cr1066","volume":"11","author":"W Ullah","year":"2020","unstructured":"Ullah W, Khanal S, Khan R, et al. Efficacy of Allopurinol in Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Cardiol Res. 2020;11(4):226\u201332. https:\/\/doi.org\/10.14740\/cr1066.","journal-title":"Cardiol Res"},{"issue":"2","key":"7954_CR138","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cjca.2015.05.010","volume":"32","author":"AJ Robertson","year":"2016","unstructured":"Robertson AJ, Struthers AD. A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease. Can J Cardiol. 2016;32(2):190\u20136. https:\/\/doi.org\/10.1016\/j.cjca.2015.05.010.","journal-title":"Can J Cardiol"},{"issue":"3","key":"7954_CR139","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/rheumatology\/kex232","volume":"57","author":"JA Singh","year":"2018","unstructured":"Singh JA, Cleveland J. Allopurinol and the risk of incident peripheral arterial disease in the elderly: a US Medicare claims data study. Rheumatology (Oxford). 2018;57(3):451\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kex232.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"7954_CR140","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.5114\/aoms\/167480","volume":"19","author":"Q Fu","year":"2023","unstructured":"Fu Q, Liao H, Li Z, Chen X, et al. Preventive effects of 13 different drugs on colorectal cancer: a network meta-analysis. Arch Med Sci. 2023;19(5):1428\u201345. https:\/\/doi.org\/10.5114\/aoms\/167480.","journal-title":"Arch Med Sci"},{"key":"7954_CR141","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40058","author":"M Ganz","year":"2023","unstructured":"Ganz M, Alessandro C, Jacobs M, et al. Investigating the anti-inflammatory effect of allopurinol on the prevention of prostate cancer. Cureus. 2023. https:\/\/doi.org\/10.7759\/cureus.40058.","journal-title":"Cureus"},{"key":"7954_CR142","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1515\/JPM.2011.025","volume":"39","author":"D Boda","year":"2011","unstructured":"Boda D. Results of and further prevention of hypoxic fetal brain damage by inhibition of xanthine oxidase enzyme with allopurinol. J Perinat Med. 2011;39:441\u20134. https:\/\/doi.org\/10.1515\/JPM.2011.025.","journal-title":"J Perinat Med"},{"key":"7954_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07828-6","author":"C Engel","year":"2024","unstructured":"Engel C, R\u00fcdiger M, Benders MJNL, et al. Detailed statistical analysis plan for ALBINO: effect of allopurinol in addition to hypothermia for hypoxic-ischemic brain injury on neurocognitive outcome \u2014 a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). Trials. 2024. https:\/\/doi.org\/10.1186\/s13063-023-07828-6.","journal-title":"Trials"},{"issue":"3","key":"7954_CR144","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.semarthrit.2019.11.009","volume":"50","author":"N Schlesinger","year":"2020","unstructured":"Schlesinger N, Brunetti L. Beyond urate lowering: Analgesic and anti-inflammatory properties of allopurinol. Semin Arthritis Rheumatol. 2020;50(3):444\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.11.009.","journal-title":"Semin Arthritis Rheumatol"},{"issue":"4","key":"7954_CR145","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1046\/j.1365-2125.1999.00041.x","volume":"48","author":"K Turnheim","year":"1999","unstructured":"Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999;48(4):501\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00041.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"7954_CR146","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1755-5922.2010.00243.x","volume":"30","author":"N Jia","year":"2012","unstructured":"Jia N, Dong P, Ye Y, Qian C, Dai Q. Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction. Cardiovasc Ther. 2012;30(2):117\u2013. https:\/\/doi.org\/10.1111\/j.1755-5922.2010.00243.x. 23.","journal-title":"Cardiovasc Ther"},{"issue":"10","key":"7954_CR147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046668","volume":"7","author":"F Derbre","year":"2012","unstructured":"Derbre F, Ferrando B, Gomez-Cabrera MC, Sanchis-Gomar F, Martinez-Bello VE, Olaso-Gonzalez G, et al. Inhibition of xanthine oxidase by allopurinol prevents skeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases. PLoS One. 2012;7(10):e46668. https:\/\/doi.org\/10.1371\/journal.pone.0046668.","journal-title":"PLoS One"},{"issue":"1","key":"7954_CR148","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41598-018-21552-1","volume":"8","author":"B Ferrando","year":"2018","unstructured":"Ferrando B, Gomez-Cabrera MC, Salvador-Pascual A, Puchades C, Derbr\u00e9 F, Gratas-Delamarche A, Laparre L, Olaso-Gonzalez G, Cerda M, Viosca E, Alabajos A, Sebasti\u00e1 V, Alberich-Bayarri A, Garc\u00eda-Castro F, Vi\u00f1a J. Allopurinol partially prevents disuse muscle atrophy in mice and humans. Sci Rep. 2018;8(1):3549. https:\/\/doi.org\/10.1038\/s41598-018-21552-1.","journal-title":"Sci Rep"},{"issue":"2","key":"7954_CR149","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/ATVBAHA.111.234559","volume":"32","author":"A Kushiyama","year":"2012","unstructured":"Kushiyama A, Okubo H, Sakoda H, Kikuchi T, Fujishiro M, Sato H, Kushiyama S, Iwashita M, Nishimura F, Fukushima T, Nakatsu Y, Kamata H, Kawazu S, Higashi Y, Kurihara H, Asano T. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol. 2012;32(2):291\u20138. https:\/\/doi.org\/10.1161\/ATVBAHA.111.234559.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7954_CR150","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1152\/ajpregu.00483.2016","volume":"313","author":"G Lastra","year":"2017","unstructured":"Lastra G, Manrique C, Jia G, Aroor AR, Hayden MR, Barron BJ, et al. Xanthine oxidase inhibition protects against Western diet-induced aortic stiffness and impaired vasorelaxation in female mice. Am J Physiol Regul Integr Comp Physiol. 2017;313(2):R67\u201377. https:\/\/doi.org\/10.1152\/ajpregu.00483.2016.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"7954_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260844","author":"KH van der Pol","year":"2021","unstructured":"van der Pol KH, Wever KE, Verbakel M, et al. Allopurinol to reduce cardiovascular morbidity and mortality: a systematic review and meta-analysis. PLoS One. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0260844.","journal-title":"PLoS One"},{"issue":"1","key":"7954_CR152","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, Lopes LM, Eisenreich MA, Hickmann S, Bongiorno GK, d\u2019Avila R, Morsch ALB, da Silva Stein F, Campos GGD. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18(1):24. https:\/\/doi.org\/10.1186\/s12872-018-0757-9.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"7954_CR153","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-017-0839-5","volume":"78","author":"AFG Cicero","year":"2018","unstructured":"Cicero AFG, Pirro M, Watts GF, Mikhailidis DP, Banach M, Sahebkar A. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2018;78(1):99\u2013109. https:\/\/doi.org\/10.1007\/s40265-017-0839-5.","journal-title":"Drugs"},{"key":"7954_CR154","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharmthera.2016.12.004","volume":"172","author":"ON Okafor","year":"2017","unstructured":"Okafor ON, Farrington K, Gorog DA. Allopurinol as a therapeutic option in cardiovascular disease. Pharmacol Ther. 2017;172:139\u201350. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.12.004.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"7954_CR155","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/eurheartj\/ehad014","volume":"44","author":"G Liuzzo","year":"2023","unstructured":"Liuzzo G, Patrono C. Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease. Eur Heart J. 2023;44(12):1016\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/ehad014","journal-title":"Eur Heart J"},{"issue":"2","key":"7954_CR156","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ijcard.2009.08.037","volume":"145","author":"E Rentoukas","year":"2010","unstructured":"Rentoukas E, Tsarouhas K, Tsitsimpikou C, Lazaros G, Deftereos S, Vavetsi S. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145(2):257\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2009.08.037.","journal-title":"Int J Cardiol"},{"issue":"2","key":"7954_CR157","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1172\/JCI20641","volume":"114","author":"DP Judge","year":"2004","unstructured":"Judge DP, Biery NJ, Keene DR, et al. Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest. 2004;114(2):172\u2013. https:\/\/doi.org\/10.1172\/JCI20641. 81.","journal-title":"J Clin Invest"},{"key":"7954_CR158","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3389\/fphys.2017.00933","volume":"8","author":"F Jim\u00e9nez-Altay\u00f3","year":"2017","unstructured":"Jim\u00e9nez-Altay\u00f3 F, Siegert AM, Bonorino F, et al. Differences in the Thoracic Aorta by Region and Sex in a Murine Model of Marfan Syndrome. Front Physiol. 2017;8:933. https:\/\/doi.org\/10.3389\/fphys.2017.00933.","journal-title":"Front Physiol"},{"issue":"20","key":"7954_CR159","doi-asserted-by":"publisher","first-page":"e015773","DOI":"10.1161\/JAHA.119.015773","volume":"9","author":"Y Tashima","year":"2020","unstructured":"Tashima Y, He H, Cui JZ, et al. Androgens Accentuate TGF-\u03b2 Dependent Erk\/Smad Activation During Thoracic Aortic Aneurysm Formation in Marfan Syndrome Male Mice. J Am Heart Assoc. 2020;9(20):e015773. https:\/\/doi.org\/10.1161\/JAHA.119.015773.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"7954_CR160","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s41431-020-0666-0","volume":"28","author":"I Gerdes Gyuricza","year":"2020","unstructured":"Gerdes Gyuricza I, de Souza R, Farinha-Arcieri LE, et al. Is HSPG2 a modifier gene for Marfan syndrome? Eur J Hum Genet. 2020;28(9):1292\u20136. https:\/\/doi.org\/10.1038\/s41431-020-0666-0.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"7954_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165587","volume":"1866","author":"P Nolasco","year":"2020","unstructured":"Nolasco P, Fernandes CG, Ribeiro-Silva JC, et al. Impaired vascular smooth muscle cell force-generating capacity and phenotypic deregulation in Marfan syndrome mice. Biochimica et Biophysica Acta (BBA). 2020;1866(1):165587. https:\/\/doi.org\/10.1016\/j.bbadis.2019.165587.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"7954_CR162","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09665-w","volume":"15","author":"RB de Souza","year":"2025","unstructured":"de Souza RB, Cassiano LL, Barnowski P, et al. Exploring thoracic aorta ECM alterations in Marfan syndrome: insights into aorta wall structure. Sci Rep. 2025;15(1):26665. https:\/\/doi.org\/10.1038\/s41598-025-09665-w.","journal-title":"Sci Rep"},{"key":"7954_CR163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014136","author":"BL Lima","year":"2010","unstructured":"Lima BL, Santos EJC, Fernandes GR, et al. A new mouse model for marfan syndrome presents phenotypic variability associated with the genetic background and overall levels of Fbn1 expression. PLoS One. 2010. https:\/\/doi.org\/10.1371\/journal.pone.0014136.","journal-title":"PLoS One"},{"key":"7954_CR164","doi-asserted-by":"publisher","first-page":"108001","DOI":"10.1016\/j.exer.2020.108001","volume":"194","author":"EM Feneck","year":"2020","unstructured":"Feneck EM, Souza RB, Lewis PN, et al. Developmental abnormalities in the cornea of a mouse model for Marfan syndrome. Exp Eye Res. 2020;194:108001. https:\/\/doi.org\/10.1016\/j.exer.2020.108001.","journal-title":"Exp Eye Res"},{"key":"7954_CR165","doi-asserted-by":"publisher","first-page":"108461","DOI":"10.1016\/j.exer.2021.108461","volume":"204","author":"RB de Souza","year":"2021","unstructured":"de Souza RB, Gyuricza IG, Cassiano LL, et al. The mg\u2206lpn mouse model for Marfan syndrome recapitulates the ocular phenotypes of the disease. Exp Eye Res. 2021;204:108461. https:\/\/doi.org\/10.1016\/j.exer.2021.108461.","journal-title":"Exp Eye Res"},{"key":"7954_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224581","author":"RB de Souza","year":"2019","unstructured":"de Souza RB, Farinha-Arcieri LE, Catroxo MHB, et al. Association of thoracic spine deformity and cardiovascular disease in a mouse model for Marfan syndrome. PLoS One. 2019. https:\/\/doi.org\/10.1371\/journal.pone.0224581.","journal-title":"PLoS One"},{"key":"7954_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411293","author":"I Rodr\u00edguez-Rovira","year":"2023","unstructured":"Rodr\u00edguez-Rovira I, L\u00f3pez-Sainz A, Palomo-Buitrago ME, et al. Hyperuricaemia does not interfere with aortopathy in a murine model of Marfan syndrome. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241411293.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"7954_CR168","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1161\/CIRCRESAHA.112.268268","volume":"110","author":"W Xiong","year":"2012","unstructured":"Xiong W, Meisinger T, Knispel R, et al. MMP-2 regulates Erk1\/2 phosphorylation and aortic dilatation in Marfan syndrome. Circ Res. 2012;110(12):e92\u2013101. https:\/\/doi.org\/10.1161\/CIRCRESAHA.112.268268.","journal-title":"Circ Res"},{"issue":"S2","key":"7954_CR169","doi-asserted-by":"publisher","first-page":"125","DOI":"10.33594\/000000819","volume":"59","author":"K Lewandowska","year":"2025","unstructured":"Lewandowska K, Miku\u0142a-Pietrasik J, Ksi\u0105\u017cek K, et al. Allopurinol Attenuates Senescence and Oxidative Stress in Endothelial Cells Exposed to Serum from Hypertensive Patients with Hyperuricemia - a Pilot Study. Cell Physiol Biochem. 2025;59(S2):125\u201337. https:\/\/doi.org\/10.33594\/000000819.","journal-title":"Cell Physiol Biochem"},{"issue":"9","key":"7954_CR170","doi-asserted-by":"publisher","first-page":"e037826","DOI":"10.1161\/JAHA.124.037826","volume":"14","author":"Y Chen","year":"2025","unstructured":"Chen Y, Zhu Y, Ren X, et al. Endothelial Cell Senescence in Marfan Syndrome: Pathogenesis and Therapeutic Potential of TGF-\u03b2 Pathway Inhibition. J Am Heart Assoc. 2025;14(9):e037826. https:\/\/doi.org\/10.1161\/JAHA.124.037826.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"7954_CR171","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1161\/ATVBAHA.122.318788","volume":"43","author":"L Yang","year":"2023","unstructured":"Yang L, Wu H, Luo C, et al. Urate-Lowering Therapy Inhibits Thoracic Aortic Aneurysm and Dissection Formation in Mice. Arterioscler Thromb Vasc Biol. 2023;43(6):e172\u201389. https:\/\/doi.org\/10.1161\/ATVBAHA.122.318788.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"7954_CR172","doi-asserted-by":"publisher","first-page":"CD006077","DOI":"10.1002\/14651858.CD006077.pub3","volume":"2014","author":"R Seth","year":"2014","unstructured":"Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev. 2014;2014(10):CD006077. https:\/\/doi.org\/10.1002\/14651858.CD006077.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"l","key":"7954_CR173","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S0167-5273(15)31028-7","volume":"201","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. Int J Cardio. 2015;201(l):S15\u201322. https:\/\/doi.org\/10.1016\/S0167-5273(15)31028-7.","journal-title":"Int J Cardio"},{"issue":"5","key":"7954_CR174","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1253\/circj.CJ-15-0232","volume":"79","author":"T Iso","year":"2015","unstructured":"Iso T, Kurabayashi M. Extremely low levels of serum uric acid are associated with endothelial dysfunction in humans. Circ J. 2015;79(5):978\u201380. https:\/\/doi.org\/10.1253\/circj.CJ-15-0232.","journal-title":"Circ J"},{"issue":"5","key":"7954_CR175","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1253\/circj.CJ-14-1267","volume":"79","author":"S Sugihara","year":"2015","unstructured":"Sugihara S, Hisatome I, Kuwabara M, et al. Depletion of Uric Acid Due to SLC22A12 (URAT1) Loss-of-Function Mutation Causes Endothelial Dysfunction in Hypouricemia. Circ J. 2015;79(5):1125\u2013. https:\/\/doi.org\/10.1253\/circj.CJ-14-1267. 327.","journal-title":"Circ J"},{"key":"7954_CR176","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-026-07866-7","author":"C Hou","year":"2026","unstructured":"Hou C, Zheng A, Zheng X, et al. The non-linear relationship between serum uric acid and cardiovascular disease risk: mechanistic insights and clinical implications. Cardiovasc Drugs Ther. 2026. https:\/\/doi.org\/10.1007\/s10557-026-07866-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7954_CR177","doi-asserted-by":"publisher","first-page":"5392454","DOI":"10.1155\/2020\/5392454","volume":"2020","author":"ME Soto","year":"2020","unstructured":"Soto ME, Manzano-Pech LG, Guarner-Lans V, et al. Oxidant\/Antioxidant Profile in the Thoracic Aneurysm of Patients with the Loeys-Dietz Syndrome. Oxid Med Cell Longev. 2020;2020:5392454. https:\/\/doi.org\/10.1155\/2020\/5392454.","journal-title":"Oxid Med Cell Longev"},{"key":"7954_CR178","doi-asserted-by":"publisher","unstructured":"Aizpuru-Gomez A, Rodr\u00edguez-Rovira I, Abdalla N, et al. Allopurinol improves cardiovascular phenotypes of a mouse model for Williams\u2013Beuren syndrome reducing redox stress. bioRxiv. 2025;08. https:\/\/doi.org\/10.1101\/2025.08.06.668870.","DOI":"10.1101\/2025.08.06.668870"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07954-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:45:31Z","timestamp":1789623931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":178,"alternative-id":["7954"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07954-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}